Sign-up for our newsletter
Protocols & Methods
Reagents & Resources
IMPC / KOMP Data
Research Assistant Professor
Targeting Neuromedin S as a novel therapy for advanced diabetic kidney disease
Currently the management of diabetic kidney disease focuses on the treatment of hyperglycemia and high blood pressure. Clinical trials intensifying the management of glycemia or maximal treatment of high blood pressure have not decreased the risk of death or end-stage renal disease (ESRD), suggesting that other mechanism(s) may be involved in the pathogenesis of diabetic kidney disease and that new therapeutic agents are urgently needed. In a proteomic and microarray screen, we identified neuromedin s (NMS) – a poorly characterised neuropeptide - as a major factor secreted by injured endothelial cells that can directly cause podocyte injury and enhance TGF-ß1-induced activation of renal fibroblasts in vitro. Our subsequent studies identified marked up-regulation of NMS production by endothelial cells in human and experimental diabetic kidney disease. Furthermore, our exciting preliminary data shows that NMS deficient (NMS-/-) mice are significantly protected from renal interstitial fibrosis in the unilateral ureteral obstruction (UUO) model - the first study to identify a role for NMS in tissue fibrosis. In addition, we have generated a neutralising mouse anti-mouse NMS antibody (a-NMS Ab) for use as a pharmacologic NMS inhibitor. Administration of a-NMS Ab significantly decreases renal interstitial fibrosis in UUO. NMS is strongly upregulated in renal endothelial cells in advanced diabetic renal disease in a type II diabetes model, eNOS-/-db/db mice. Based on our compelling preliminary data, we hypothesis that NMS is a novel mediator of progressive diabetic kidney disease through inducing podocyte damage and promoting renal fibrosis. We will test whether administration of anti-NMS Ab will retard or even reverse the development and progression of diabetic nephropathy in type 2 diabetes model, eNOS-/-db/db mice. In addition, the direct effect of NMS on podocytes and mesangial cells will be investigated in vitro. This project will provide a major advance in our understanding of the role of NMS in the induction and progression of diabetic renal disease. The positive results will have clear translational potential as a new therapy for diabetic nephropathy, as well as for other diabetic complications.
Drag a column header and drop it here to group by that column
Targeting Neuromedin S as a novel therapy for advanced diabetic kidney disease (Li, Jinhua)
View Progress Report Document
No uploaded documents found.
No publications found.
No uploaded documents found.
No protocols found.
The DiaComp Steering Committee is the governing body of the consortium. The principle function of this committee is to guide the scientific direction of the consortium. This is accomplished by creating various subcommittees necessary to advance the scientific goals and providing guidance to the broader complications research community. Policies for the consortium are developed through consultation with the
External Evaluation Committee
The DiaComp Nephropathy Committee has the principal function of furthering the mission of the consortium with regard to diabetic kidney disease.
Curation Flag Information
New comment to be added:
No records to display.
Welcome to the DiaComp Login / Account Request Page.
Note: Passwords are case-sensitive.
Please save my Email Address on this machine.
Not a member?
If you are a funded DiaComp investigator, a member of an investigator's lab,
or an External Scientific Panel member to the consortium, please
request an account.
Forgot your password?
Enter your Email Address and
There was a problem with the page:
Safari Browser Detected...
We strive to make the DiaComp site compatable with as many browsers as possible, but some of our third party tools don't work with the Safari browser.
In order to explore this site we highly recommend using the most recent versions of the following browsers:
© 2018 DiaComp.org
All rights reserved
Please acknowledge all posters, manuscripts or scientific materials that were generated in part or whole using funds from the Diabetic Complications Consortium(DiaComp) using the following text:
Financial support for this work provided by the NIDDK Diabetic Complications Consortium (RRID:SCR_001415, www.diacomp.org), grants DK076169 and DK115255
Citation text and image have been copied to your clipboard. You may now paste them into your document. Thank you!